Opinion

Video

Emerging Data for Odronextamab in DLBCL

Panelists discuss how emerging data on odronextamab in diffuse large B-cell lymphoma suggest its potential to play a significant role in therapy, with promising results that may position it alongside or as a superior option compared with currently approved bispecifics.

Video content above is prompted by the following:

  • What do the emerging data on odronextamab in diffuse large B-cell lymphoma suggest about its future role in therapy, and how does it compare to currently approved bispecifics?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
4 experts are featured in this series.
4 experts are featured in this series.
5 experts in this video
4 experts are featured in this series.
5 experts in this video
5 experts are featured in this series
5 experts are featured in this series
4 experts are featured in this series.
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo